Treatment strategies in early and advanced Parkinson disease

Neurologic Clinics

Volumn 33, Issue 1, 2015, Pages 19-37

  Ossig, Christiana ^a,b   Reichmann, Heinz ^a  

^a DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

^b CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

Continuous dopaminergic stimulation; Dopamine agonists; Dyskinesia; Hypokinesia; Levodopa; Parkinson's disease

Indexed keywords

AMANTADINE; ANTIPARKINSON AGENT; BUDIPINE; CATECHOL METHYLTRANSFERASE; CHOLINERGIC RECEPTOR BLOCKING AGENT; DOPAMINE RECEPTOR STIMULATING AGENT; LEVODOPA; MONOAMINE OXIDASE B INHIBITOR;

ANKLE EDEMA; ARTICLE; BRADYKINESIA; BRAIN DEPTH STIMULATION; DISEASE COURSE; DRUG DELIVERY SYSTEM; DRUG SAFETY; DYSKINESIA; HUMAN; IDIOPATHIC DISEASE; MUSCLE RIGIDITY; NAUSEA; NONHUMAN; ORTHOSTATIC HYPOTENSION; PALLIATIVE THERAPY; PARASOMNIA; PARKINSON DISEASE; PARKINSONISM; PATHOPHYSIOLOGY; PRACTICE GUIDELINE; QUALITY OF LIFE; REM SLEEP; TIME TO TREATMENT; TREATMENT OUTCOME; TREATMENT RESPONSE; TREMOR; UNIFIED PARKINSON DISEASE RATING SCALE;

ANTIPARKINSON AGENTS; HUMANS; PARKINSON DISEASE;

EID: 84918556447     PISSN: 07338619     EISSN: 15579875     Source Type: Journal    
DOI: 10.1016/j.ncl.2014.09.009     Document Type: Review

References (74)

1. Braak H, Del Tredici K, Rub U, et al. Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol Aging 2003;24(2):197-211.
2. Braak H, Del Tredici K, Bratzke H, et al. Staging of the intracerebral inclusion body pathology associated with idiopathic Parkinson's disease (preclinical and clinical stages). J Neurol 2002;249(Suppl 3):III/1-5.
3. Haehner A, Boesveldt S, Berendse HW, et al. Prevalence of smell loss in Parkinson's disease-a multicenter study. Parkinsonism Relat Disord 2009;15(7):490-4.
4. Deeb J, Shah M, Muhammed N, et al. A basic smell test is as sensitive as a dopamine transporter scan: comparison of olfaction, taste and DaTSCAN in the diagnosis of Parkinson's disease. QJM 2010;103(12):941-52.
5. Oka H, Toyoda C, Yogo M, et al. Cardiovascular dysautonomia in de novo Parkinson's disease without orthostatic hypotension. Eur J Neurol 2011;18(2):286-92.
6. Schenck CH, Mahowald MW. REM sleep behavior disorder: clinical, developmental, and neuroscience perspectives 16 years after its formal identification in SLEEP. Sleep 2002;25(2):120-38.
7. Schenck CH, Montplaisir JY, Frauscher B, et al. Rapid eye movement sleep behavior disorder: devising controlled active treatment studies for symptomatic and neuroprotective therapy-a consensus statement from the International Rapid Eye Movement Sleep Behavior Disorder Study Group. Sleep Med 2013;14(8): 795-806.
8. Iranzo A, Molinuevo JL, Santamaria J, et al. Rapid-eye-movement sleep behaviour disorder as an early marker for a neurodegenerative disorder: a descriptive study. Lancet Neurol 2006;5(7):572-7.
9. Postuma RB, Gagnon JF, Vendette M, et al. Quantifying the risk of neurodegenerative disease in idiopathic REM sleep behavior disorder. Neurology 2009; 72(15):1296-300.
10. Iranzo A, Tolosa E, Gelpi E, et al. Neurodegenerative disease status and postmortem pathology in idiopathic rapid-eye-movement sleep behaviour disorder: an observational cohort study. Lancet Neurol 2013;12(5):443-53.
11. Olichney JM, Murphy C, Hofstetter CR, et al. Anosmia is very common in the Lewy body variant of Alzheimer's disease. J Neurol Neurosurg Psychiatr 2005; 76(10):1342-7.
12. Jennum P, Mayer G, Ju YE, Postuma R. Morbidities in rapid eye movement sleep behavior disorder. Sleep Med 2013;14(8):782-7.
13. Aurora RN, Zak RS, Maganti RK, et al. Best practice guide for the treatment of REM sleep behavior disorder (RBD). J Clin Sleep Med 2010;6(1):85-95.
14. Troeung L, Egan SJ, Gasson N. A meta-analysis of randomised placebocontrolled treatment trials for depression and anxiety in Parkinson's disease. PLoS One 2013;8(11):e79510.
15. Liu J, Dong J, Wang L, et al. Comparative efficacy and acceptability of antidepressants in Parkinson's disease: a network meta-analysis. PLoS One 2013; 8(10):e76651.
16. Morens DM, Davis JW, Grandinetti A, et al. Epidemiologic observations on Parkinson's disease: incidence and mortality in a prospective study of middle-aged men. Neurology 1996;46(4):1044-50.
17. Hoehn MM, Yahr MD. Parkinsonism: onset, progression and mortality. Neurology 1967;17(5):427-42.
18. Gille G, Hung ST, Reichmann H, et al. Oxidative stress to dopaminergic neurons as models of Parkinson's disease. Ann N Y Acad Sci 2004;1018:533-40.
19. Michel PP, Hefti F. Toxicity of 6-hydroxydopamine and dopamine for dopaminergic neurons in culture. J Neurosci Res 1990;26(4):428-35.
20. Fahn S, Oakes D, Shoulson I, et al. Levodopa and the progression of Parkinson's disease. N Engl J Med 2004;351(24):2498-508.
21. Olanow CW, Obeso JA, Stocchi F. Continuous dopamine-receptor treatment of Parkinson's disease: scientific rationale and clinical implications. Lancet Neurol 2006;5(8):677-87.
22. Kostic V, Przedborski S, Flaster E, et al. Early development of levodopa-induced dyskinesias and response fluctuations in young-onset Parkinson's disease. Neurology 1991;41(2 (Pt 1)):202-5.
23. Palhagen S, Heinonen E, Hagglund J, et al. Selegiline slows the progression of the symptoms of Parkinson disease. Neurology 2006;66(8):1200-6.
24. Parkinson Study Group. A controlled trial of rasagiline in early Parkinson disease: the TEMPO Study. Arch Neurol 2002;59(12):1937-43.
25. Hauser RA, Lew MF, Hurtig HI, et al. Long-term outcome of early versus delayed rasagiline treatment in early Parkinson's disease. Mov Disord 2009;24(4):564-73.
26. Rascol O, Fitzer-Attas CJ, Hauser R, et al. A double-blind, delayed-start trial of rasagiline in Parkinson's disease (the ADAGIO study): prespecified and posthoc analyses of the need for additional therapies, changes in UPDRS scores, and non-motor outcomes. Lancet Neurol 2011;10(5):415-23.
27. Olanow CW, Rascol O, Hauser R, et al. A double-blind, delayed-start trial of rasagiline in Parkinson's disease. N Engl J Med 2009;361(13):1268-78.
28. Parkinson Study Group. A randomized placebo-controlled trial of rasagiline in levodopa-treated patients with Parkinson disease and motor fluctuations: the PRESTO study. Arch Neurol 2005;62(2):241-8.
29. Stocchi F, Rabey JM. Effect of rasagiline as adjunct therapy to levodopa on severity of OFF in Parkinson's disease. Eur J Neurol 2011;18(12):1373-8.
30. Rascol O, Brooks DJ, Melamed E, et al. Rasagiline as an adjunct to levodopa in patients with Parkinson's disease and motor fluctuations (LARGO, Lasting effect in Adjunct therapy with Rasagiline Given Once daily, study): a randomised, double-blind, parallel-group trial. Lancet 2005;365(9463):947-54.
31. Deane KH, Spieker S, Clarke CE. Catechol-O-methyltransferase inhibitors for levodopa-induced complications in Parkinson's disease. Cochrane Database Syst Rev 2004;(4):CD004554.
32. Entacapone improves motor fluctuations in levodopa-treated Parkinson's disease patients. Parkinson Study Group. Ann Neurol 1997;42(5):747-55.
33. Stocchi F, Rascol O, Kieburtz K, et al. Initiating levodopa/carbidopa therapy with and without entacapone in early Parkinson disease: the STRIDE-PD study. Ann Neurol 2010;68(1):18-27.
34. Ferreira JJ, Katzenschlager R, Bloem BR, et al. Summary of the recommendations of the EFNS/MDS-ES review on therapeutic management of Parkinson's disease. Eur J Neurol 2013;20(1):5-15.
35. Reichmann H. Budipine in Parkinson's tremor. J Neurol Sci 2006;248(1-2):53-5.
36. Katzenschlager R, Sampaio C, Costa J, et al. Anticholinergics for symptomatic management of Parkinson's disease. Cochrane Database Syst Rev 2003;(2):CD003735.
37. Zou L, Jankovic J, Rowe DB, et al. Neuroprotection by pramipexole against dopamine- and levodopa-induced cytotoxicity. Life Sci 1999;64(15):1275-85.
38. Iida M, Miyazaki I, Tanaka K, et al. Dopamine D2 receptor-mediated antioxidant and neuroprotective effects of ropinirole, a dopamine agonist. Brain Res 1999; 838(1-2):51-9.
39. Trenkwalder C, Kies B, Rudzinska M, et al. Rotigotine effects on early morning motor function and sleep in Parkinson's disease: a double-blind, randomized, placebo-controlled study (RECOVER). Mov Disord 2011;26(1):90-9.
40. Parkinson Study Group. Pramipexole vs levodopa as initial treatment for Parkinson disease: a randomized controlled trial. Parkinson Study Group. JAMA 2000;284(15):1931-8.
41. Rascol O, Brooks DJ, Korczyn AD, et al. A five-year study of the incidence of dyskinesia in patients with early Parkinson's disease who were treated with ropinirole or levodopa. 056 Study Group. N Engl J Med 2000;342(20):1484-91.
42. Weiss HD, Marsh L. Impulse control disorders and compulsive behaviors associated with dopaminergic therapies in Parkinson disease. Neurol Clin Pract 2012; 2(4):267-74.
43. Barone P, Poewe W, Albrecht S, et al. Pramipexole for the treatment of depressive symptoms in patients with Parkinson's disease: a randomised, double-blind, placebo- controlled trial. Lancet Neurol 2010;9(6):573-80.
44. Frankel JP, Lees AJ, Kempster PA, et al. Subcutaneous apomorphine in the treatment of Parkinson's disease. J Neurol Neurosurg Psychiatr 1990;53(2):96-101.
45. Bowron A. Practical considerations in the use of apomorphine injectable. Neurology 2004;62(6 Suppl 4):S32-6.
46. Deleu D, Hanssens Y, Northway MG. Subcutaneous apomorphine: an evidencebased review of its use in Parkinson's disease. Drugs Aging 2004;21(11): 687-709.
47. Manson AJ, Hanagasi H, Turner K, et al. Intravenous apomorphine therapy in Parkinson's disease: clinical and pharmacokinetic observations. Brain 2001;124(Pt 2): 331-40.
48. Stocchi F, Vacca L, De Pandis MF, et al. Subcutaneous continuous apomorphine infusion in fluctuating patients with Parkinson's disease: long-term results. Neurol Sci 2001;22(1):93-4.
49. Antonini A, Mancini F, Canesi M, et al. Duodenal levodopa infusion improves quality of life in advanced Parkinson's disease. Neurodegener Dis 2008;5(3-4):244-6.
50. Eggert K, Schrader C, Hahn M, et al. Continuous jejunal levodopa infusion in patients with advanced Parkinson disease: practical aspects and outcome of motor and non-motor complications. Clin Neuropharmacol 2008;31(3):151-66.
51. Honig H, Antonini A, Martinez-Martin P, et al. Intrajejunal levodopa infusion in Parkinson's disease: a pilot multicenter study of effects on nonmotor symptoms and quality of life. Mov Disord 2009;24(10):1468-74.
52. Charles PD, Van Blercom N, Krack P, et al. Predictors of effective bilateral subthalamic nucleus stimulation for PD. Neurology 2002;59(6):932-4.
53. Russmann H, Ghika J, Villemure JG, et al. Subthalamic nucleus deep brain stimulation in Parkinson disease patients over age 70 years. Neurology 2004;63(10): 1952-4.
54. Saint-Cyr JA, Trepanier LL, Kumar R, et al. Neuropsychological consequences of chronic bilateral stimulation of the subthalamic nucleus in Parkinson's disease. Brain 2000;123(Pt 10):2091-108.
55. Kleiner-Fisman G, Herzog J, Fisman DN, et al. Subthalamic nucleus deep brain stimulation: summary and meta-analysis of outcomes. Mov Disord 2006; 21(Suppl 14):S290-304.
56. Krack P, Batir A, Van Blercom N, et al. Five-year follow-up of bilateral stimulation of the subthalamic nucleus in advanced Parkinson's disease. N Engl J Med 2003; 349(20):1925-34.
57. Schupbach WM, Chastan N, Welter ML, et al. Stimulation of the subthalamic nucleus in Parkinson's disease: a 5 year follow up. J Neurol Neurosurg Psychiatr 2005;76(12):1640-4.
58. Deep-Brain Stimulation for Parkinson's Disease Study Group. Deep-brain stimulation of the subthalamic nucleus or the pars interna of the globus pallidus in Parkinson's disease. N Engl J Med 2001;345(13):956-63.
59. Ghika J, Villemure JG, Fankhauser H, et al. Efficiency and safety of bilateral contemporaneous pallidal stimulation (deep brain stimulation) in levodoparesponsive patients with Parkinson's disease with severe motor fluctuations: a 2-year follow-up review. J Neurosurg 1998;89(5):713-8.
60. Voon V, Krack P, Lang AE, et al. A multicentre study on suicide outcomes following subthalamic stimulation for Parkinson's disease. Brain 2008;131(Pt 10): 2720-8.
61. DATATOP: a multicenter controlled clinical trial in early Parkinson's disease. Parkinson Study Group. Arch Neurol 1989;46(10):1052-60.
62. Jankovic J, Gilden JL, Hiner BC, et al. Neurogenic orthostatic hypotension: a double-blind, placebo-controlled study with midodrine. Am J Med 1993;95(1): 38-48.
63. Schoffer KL, Henderson RD, O'Maley K, et al. Nonpharmacological treatment, fludrocortisone, and domperidone for orthostatic hypotension in Parkinson's disease. Mov Disord 2007;22(11):1543-9.
64. Parkes JD. Domperidone and Parkinson's disease. Clin Neuropharmacol 1986; 9(6):517-32.
65. Gunzler SA. Apomorphine in the treatment of Parkinson disease and other movement disorders. Expert Opin Pharmacother 2009;10(6):1027-38.
66. Shotbolt P, Samuel M, David A. Quetiapine in the treatment of psychosis in Parkinson's disease. Ther Adv Neurol Disord 2010;3(6):339-50.
67. Seppi K, Weintraub D, Coelho M, et al. The Movement Disorder Society evidencebased medicine review update: treatments for the non-motor symptoms of Parkinson's disease. Mov Disord 2011;26(Suppl 3):S42-80.
68. Bermejo PE, Ruiz-Huete C, Anciones B. Zonisamide in managing impulse control disorders in Parkinson's disease. J Neurol 2010;257(10):1682-5.
69. Hicks CW, Pandya MM, Itin I, et al. Valproate for the treatment of medicationinduced impulse-control disorders in three patients with Parkinson's disease. Parkinsonism Relat Disord 2011;17(5):379-81.
70. Bermejo PE. Topiramate in managing impulse control disorders in Parkinson's disease. Parkinsonism Relat Disord 2008;14(5):448-9.
71. Thomas A, Bonanni L, Gambi F, et al. Pathological gambling in Parkinson disease is reduced by amantadine. Ann Neurol 2010;68(3):400-4.
72. Sriram A, Ward HE, Hassan A, et al. Valproate as a treatment for dopamine dysregulation syndrome (DDS) in Parkinson's disease. J Neurol 2013;260(2):521-7.
73. Lagalla G, Millevolte M, Capecci M, et al. Botulinum toxin type A for drooling in Parkinson's disease: a double-blind, randomized, placebo-controlled study. Mov Disord 2006;21(5):704-7.
74. Ha AD, Jankovic J. Pain in Parkinson's disease. Mov Disord 2012;27(4):485-91.